Summary Information:
Aadi Bioscience Inc. Common Stock
NASDAQ:AADI
email
admin@troach.net 		Our Main Pages
Stocks.TRoach.Net
TRoach.Org
TRoach.Net
NOTE: This page is for evaluation of a JFF Project.
This page is NOT updated on a regular basis.
Information on this page should NOT be used for investment purposes.
Aadi Bioscience Inc. Common Stock
Exchange: NASDAQ
Symbol: AADI
SEC CIK: 0001422142
Phone: 424-473-8055
17383 SUNSET AVENUE
SUITE A250
PACIFIC PALISADES CA 90272
CEO: ). The Company's third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924's exclusive licensor, Gossamer Bio, Inc.. In January 2021, the Company announced that it had initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company's clinical assets and cash resources.
Price Quote by TradingView
Price when page updated: 5.3063 Date: 2023-11-30
Company Website:
www.aerpio.com

_Description: Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which the Company believes that activation of Tie2 may have therapeutic potential. The Company's lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase (\

IPO YEAR:

Sector:
Health Care
 Industry:
Biotechnology: Pharmaceutical Preparations
ADRTSO:

MarketCap:
130141571.00
 Beta:
4.67286890635086
52 Week High:
32.99
 52 Week Low:
0.9541
 52 Week Change:
23.61904761904762
Short Interest:

Short Date:

Shares Outstanding:
20894029
Dividend Rate:
0
 Dividend Yield:
0.00%
ExDividend Date:

Latest EPS:

Latest EPS Date:
9 Nov 2022
Float:
0
return on Equity:
-103.90%
 Consensus EPS:

Number Of Estimates:
EPS Surprise Dollar:

Eps Surprise Percent:

EBITDA:
N/A
ttmEPS:
0
 Revenue:
N/A
 Gross Profit:
Cash:

Debt:

Institution Percent:
64.80%
Revenue Percent:

Revenue Per Employee:

Insider Percent:
13.54%
Return on Assets:
-90.50%
 Return on Capital:

Profit Margin:
-
Price to Sales:
42.54
 Price To Book:
2.55
 Short Ratio:
4.21
PE Ratio:
0
 Employees:
12
 1Y Guesstimate
34.178:2.0:5


__The following are links to various summary and news pages for
__Aadi Bioscience Inc. Common Stock [ AADI ].

__Note: Some Links might not have information for the company.


finance.Yahoo.com money.CNN.com NASDAQ research
WalletInvestor.com WSJ.com MarketBeat.com
finviz.com WallMine.com TheGlobeandMail.com
stock1010.com
NASDAQ - General Info SEC Insider Report Ownership Summary
Dividend History insiderbuyingselling.com
Facebook search Twitter search LinkedIn search
PRnewsWire.Com Google Forecast
tdameritrade.com BarChart.com
SeekingAlpha.com Markets.FT.com stocktwits.com
FinTel.io Ldmicro.com bloomberg.com
MarketWatch.com Reuters.com businessinsider.com
fool.com barrons.com zacks.com
GuruFocus.com Investing.com tipranks.com
thestreet.com nytimes.com earningswhispers.com
marketchameleon.com sunshineavenue.com stockinvest.us
stockanalysis.com stockconsultant.com ycharts.com
financialcontent.com docoh.com foxbusiness.com
cnbc.com investorsobserver.com tradingview.com
investopedia.com tmxmoney.com invest.cnyes.com
ask.com bing.com brave.com
duckduckgo.com ecosia.org excite.com
exalead.com gibiru.com hotbot.com
www.info.com infospace.com lycos.com
lukol.com metacrawler.com mojeek.com
becovi.com searx.thegpm.org search.com
swisscows.com webcrawler.com yahoo.com
yandex.com yep.com you.com




INDEX



Page design by: TRoach
Page Last Updated: 2023-11-30